Morschhauser F, et al. - Given the promising results seen with lenalidomide and rituximab, researchers performed this phase 1b study to test the safety as well as the efficacy of lenalidomide combined with obinutuzumab (GALEN) in patients aged ≥ 18 years with relapsed/refractory follicular B-cell lymphoma (FL) following rituximab-containing therapy. For these patients, dose was escalated in a 3+3 design based on dose-limiting toxicity during cycle 1 to establish the maximum tolerated dose. Findings demonstrated the good tolerability as well as the efficacy of oral lenalidomide plus obinutuzumab. The most common adverse events were constipation, neutropenia, and asthenia. Of the grade 3/4 adverse events, 64.3% were neutropenia/neutrophil decrease, but with no febrile neutropenia. The recommended dose of lenalidomide was 20 mg based on the risk of grade 3/4 neutropenia.